Goldman Sachs Upgrades BioNTech (BNTX) to Buy, Raises Price Target to $142
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: stocktwits
- Oncology Strategy: BioNTech is strengthening its oncology portfolio as it pivots away from the Covid-19 vaccine Comirnaty, planning seven late-stage data readouts in 2026, indicating its potential in the oncology field.
- Stock Price Surge: Following Goldman Sachs' upgrade of BioNTech from 'Neutral' to 'Buy', BNTX shares rose 3% on Friday, with the price target increased from $115 to $142, representing a potential upside of approximately 34%.
- Market Sentiment: Retail sentiment on Stocktwits for BNTX remained in the 'bullish' territory over the past 24 hours, although some users expressed concerns regarding BioNTech's recent acquisition of CureVac, highlighting market attention on its oncology strategy.
- Future Outlook: BioNTech aims to become a multi-product oncology company by 2030, despite not expecting to recognize revenue from any oncology product sales in 2026, indicating a mix of risks and opportunities in its long-term strategy.
Analyst Views on BNTX
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 139.27 USD with a low forecast of 107.00 USD and a high forecast of 181.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
13 Buy
3 Hold
0 Sell
Strong Buy
Current: 106.070
Low
107.00
Averages
139.27
High
181.00
Current: 106.070
Low
107.00
Averages
139.27
High
181.00
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
